Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | PPARA | Q07869 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10106383 | 0.91 | SMN1; SMN2 (0.40) | NPC1RAB9ASMN1; SMN2MAPK1HTT | |
| SCHEMBL10106322 | 0.83 | RAB9A (0.39) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL10106346 | 0.82 | NPC1 (0.39) | NPC1RAB9ASMN1; SMN2PPARAMAPT | |
| SCHEMBL10106336 | 0.82 | SMN1; SMN2 (0.39) | NPC1RAB9ASMN1; SMN2MEN1MAPT | |
| SCHEMBL10330556 | 0.81 | NR3C1 (0.33) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10106311 | 0.80 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10106377 | 0.78 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10106372 | 0.78 | NPC1 (0.34) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL10106337 | 0.78 | EGFR (0.41) | NPC1RAB9ASMN1; SMN2MAPT | |
| SCHEMBL7074120 | 0.78 | NPC1 (0.41) | NPC1RAB9ASMN1; SMN2MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9321739-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-8119672-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-8119672-B2 | Compounds, compositions and methods for treating or preventing pneumovirus infection and associated diseases | MICRODOSE THERAPEUTX, INC. (US) | 2012-02-21 | — | — | US | disclosed |
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | RYS DAVID J (US) | 2011-12-15 | — | — | US | disclosed |
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | RYS DAVID J (US) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110305666-A1 | COMPOUNDS, COMPOSITIONS AND METHODS FOR TREATING OR PREVENTING PNEUMOVIRUS INFECTION AND ASSOCIATED DISEASES | TTPA, HAVCR2, PML | NPC1 215/4885RAB9A 2880/4885SMN1; SMN2 1044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.